Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Articles tagged with "IgG4-RD"

Potential Biologic Drug Treatment for IgG4-RD Identified

Deborah Levenson  |  March 6, 2025

Inebilizumab reduces the risk of immunoglobulin G4-related disease (IgG4-RD) flares and increases the likelihood of flare-free, complete remission at one year, a recent study shows.1 The randomized, doubleblind, placebo-controlled MITIGATE trial showed that inebilizumab reduced the risk of IgG4-RD symptoms by 87%, compared with placebo. About IgG4-RD IgG4-RD is chronic, rare condition that has, so…

Retroperitoneal Fibrosis & IgG4-Related Disease

Mithu Maheswaranathan, MD  |  December 11, 2024

WASHINGTON, D.C.—Retroperitoneal fibrosis (RPF) is often a challenging diagnosis to make, given a lack of serologic biomarkers and often difficulty in accessing tissue for biopsy, especially in cases confined to the retroperitoneum. The topic of retroperitoneal fibrosis was discussed during the CARE to Test Your Knowledge: Retroperitoneal Fibrosis session at ACR Convergence 2024. John Stone,…

Serum Interleukin 6 Levels May Predict Presentation of IgG4-Related Disease

Lara C. Pullen, PhD  |  May 11, 2020

A retrospective study found serum interleukin 6 levels at the onset of IgG4-RD may significantly correlate with clinical inflammatory parameters and the involvement of the bile duct, liver and spleen…

New ACR/EULAR IgG4 Classification Criteria Introduced

Arthritis & Rheumatology  |  January 2, 2020

Immunoglobulin G4-related disease (IgG4-RD) can cause fibroinflammatory lesions in nearly any organ. Correlation among clinical, serologic, radiologic and pathologic data is required for diagnosis. ACR/EULAR classification criteria for IgG4-RD have now been developed and validated in a large cohort of patients…

Draft Classification Criteria for IgG4-Related Disease Introduced

Lara C. Pullen, PhD  |  March 19, 2019

CHICAGO—John H. Stone, MD, MPH, director of clinical rheumatology at Massachusetts General Hospital, Boston, took the stage at the 2018 ACR/ARHP Annual Meeting to present, for the first time, a draft of new classification criteria for IgG4-related disease (IgG4-RD), a project supported by both the ACR and EULAR. Even though it was the last day…

IgG4-Related Kidney Disease: Diagnostics, Manifestations, & More

IgG4-Related Kidney Disease: Diagnostics, Manifestations & More

Despina Michailidou, MD, PhD, & Paul Cohen, MD   |  May 17, 2018

Immunoglobin G4-related disease (IgG4-RD) is a rare fibro-inflammatory disease of unknown etiology that has been recently recognized. It can cause fibro-inflammatory masses in almost every organ of the body and is associated with dense lymphoplasmacytic infiltration of IgG4-postitive plasma cells, storiform fibrosis and elevated levels of serum IgG4.1 IgG4-RD is a systemic disease that may…

Gene Signatures in IgG4-Related Disease

Lara C. Pullen, PhD  |  February 20, 2018

Research suggests prednisone treatment can selectively modulate the signatures of regulatory T (Treg) cells, eosinophils and neutrophils in patients with IgG4-related disease. The results show IgG4-related disease may result from an imbalance of immune and inflammatory cells…

International Consensus Statement on the Management & Treatment of IgG4-Related Disease

Arthritis & Rheumatology  |  June 30, 2015

IgG4-related disease (IgG4-RD) is an immune-mediated fibro-inflammatory condition that affects multiple organs and can lead to tumefactive, tissue-destructive lesions and organ failure. An international panel of experts has released a consensus statement on its management…

A Spotlight on IgG4-Related Disease

Emine Atac, MD, and John H. Stone, MD, MPH  |  January 1, 2013

What rheumatologists need to know about identifying and diagnosing immunoglobulin G4-related disease (IgG4-RD)

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences